Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain
Launched by REGENERON PHARMACEUTICALS · Oct 26, 2009
Trial Information
Current as of June 14, 2025
Terminated
Keywords
ClinConnect Summary
The duration of the study period for each participant was up to 14 weeks, including a screening period up to 2 weeks, and 12-week follow-up after the injection.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Moderate to severe abdominal pain due to chronic pancreatitis of at least 6 months duration.
- Exclusion criteria:
- • Mild pain on the Pain Intensity-Numeric Rating Scale \[PI-NRS\] at screening and randomization visits;
- • Narcotic addiction;
- • Recent pancreatic surgical or endoscopic intervention for chronic pancreatitis pain;
- • Unwillingness to use study-defined rescue analgesia exclusively.
- • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, a leading biotechnology company, is dedicated to transforming the lives of patients through innovative medicines. Founded in 1988, the company specializes in the discovery, development, and commercialization of cutting-edge therapies for serious diseases, leveraging advanced genetic technologies and a robust pipeline of novel drug candidates. With a strong focus on areas such as ophthalmology, oncology, immunology, and rare diseases, Regeneron is committed to scientific excellence and collaboration, striving to deliver safe and effective treatments that address unmet medical needs and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Arcadia, California, United States
Bell Gardens, California, United States
Monterey, California, United States
San Diego, California, United States
Stanford, California, United States
Miami, Florida, United States
St. Petersburg, Florida, United States
Marietta, Georgia, United States
Worcester, Massachusetts, United States
Lebanon, New Hampshire, United States
New York, New York, United States
Winston Salem, North Carolina, United States
Cleveland, Ohio, United States
Dallas, Texas, United States
Desoto, Texas, United States
Southlake, Texas, United States
East Sandy, Utah, United States
Patients applied
Trial Officials
Clinical Sciences & Operations
Study Director
Sanofi
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials